European Journal of Neurology, 03/09/2012Liu X et al.
Ginsenoside–Rd improved the primary outcome of acute ischaemic stroke and had an acceptable adverse–event profile.
The authors conducted a randomized, double–blind, placebo–controlled trial involving 390 patients with acute ischaemic stroke in a 3:1 ratio to receive a 14–day intravenous infusion of Ginsenoside–Rd or placebo within 72 h after the onset of stroke.
The primary end–point was the distribution of disability scores on the modified Rankin scale (mRs) at 90 days.
The efficacy analysis was based on 386 patients (Ginsenoside–Rd group: 290; placebo group: 96).
Ginsenoside–Rd significantly improved the overall distribution of scores on the mRs, as compared with the placebo (P = 0.02; odds ratios [OR], 1.74; 95% confidence interval [CI], 1.08–2.78).
There were significant differences between the two groups when they categorized the scores into 0–1 vs. 2–5 (P = 0.01; OR, 2.32; 95% CI, 1.23–4.38; 66.8% vs. 53.1%).
It also improved the National Institutes of Health Stroke Scale (NIHSS) at 15 days [P < 0.01; least squares mean (LSM), –0.77; 95% CI, –1.31 to –0.24]. Mortality and rates of adverse events were similar in the two groups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.